Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells

Biochemical and Biophysical Research Communications

Volumn 441, Issue 2, 2013, Pages 393-398

  Petri, Marcelo H ^a   Tellier, Céline ^b   Michiels, Carine ^b   Ellertsen, Ingvill ^a   Dogné, Jean Michel ^c   Bäck, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b University of Namur   (Belgium)

^c UNIVERSITY OF NAMUR   (Belgium)

Author keywords

Eicosanoids; Endothelial cells; Inflammation; Smooth muscle cells; Thromboxane prostanoid receptor

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6 OXOPROSTAGLANDIN F1 ALPHA; EV 077; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PROSTANOID RECEPTOR; THROMBOXANE A2; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SERUM; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL;

EICOSANOIDS; ENDOTHELIAL CELLS; INFLAMMATION; SMOOTH MUSCLE CELLS; THROMBOXANE PROSTANOID RECEPTOR;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; C-REACTIVE PROTEIN; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROSTAGLANDINS F; RECEPTORS, THROMBOXANE; RNA, MESSENGER; SERUM AMYLOID P-COMPONENT; THROMBOXANE A2; THROMBOXANE-A SYNTHASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888006143     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.078     Document Type: Article

References (42)

1. A. Gabrielsen, H. Qiu, M. Bäck, M. Hamberg, A.L. Hemdahl, H. Agardh, L. Folkersen, J. Swedenborg, U. Hedin, G. Paulsson-Berne, J.Z. Haeggstrom, and G.K. Hansson Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion J. Mol. Med. 88 2010 795 806
2. N. Foudi, X. Norel, M. Rienzo, L. Louedec, C. Brink, J.B. Michel, and M. Bäck Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits Am. J. Physiol. Heart Circ. Physiol. 297 2009 H1882 H1888
3. F. Stanke-Labesque, M. Bäck, B. Lefebvre, R. Tamisier, J.P. Baguet, N. Arnol, P. Levy, and J.L. Pepin Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia J. Allergy Clin. Immunol. 124 2009 364 370 370 e361-362
4. T. Cyrus, Y. Yao, T. Ding, J.M. Dogne, and D. Pratico Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice Blood 109 2007 3291 3296
5. T. Cyrus, Y. Yao, T. Ding, J.M. Dogne, and D. Pratico A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice Eur. J. Pharmacol. 561 2007 105 111
6. C. Cherdon, S. Rolin, J. Hanson, A. Ooms, L. de Leval, P. Drion, C. Michiels, B. Pirotte, B. Masereel, N. Sakalihassan, J.O. Defraigne, and J.M. Dogne BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase Prostaglandins Other Lipid Mediat. 94 2011 124 132
7. T. Kobayashi, Y. Tahara, M. Matsumoto, M. Iguchi, H. Sano, T. Murayama, H. Arai, H. Oida, T. Yurugi-Kobayashi, J.K. Yamashita, H. Katagiri, M. Majima, M. Yokode, T. Kita, and S. Narumiya Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice J. Clin. Invest. 114 2004 784 794
8. D. Pratico, and J.M. Dogne Vascular biology of eicosanoids and atherogenesis Expert Rev. Cardiovasc. Ther. 7 2009 1079 1089
9. V. Capra, M. Bäck, S.S. Barbieri, M. Camera, E. Tremoli, and G.E. Rovati Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke Med. Res. Rev. 33 2013 364 438
10. A.J. Cayatte, Y. Du, J. Oliver-Krasinski, G. Lavielle, T.J. Verbeuren, and R.A. Cohen The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice. evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler. Thromb. Vasc. Biol. 20 2000 1724 1728
11. P. Gelosa, R. Ballerio, C. Banfi, E. Nobili, A. Gianella, A. Pignieri, M. Brioschi, U. Guerrini, L. Castiglioni, V. Blanc-Guillemaud, L. Lerond, E. Tremoli, and L. Sironi Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin J. Pharmacol. Exp. Ther. 334 2010 199 205
12. L. Belhassen, G. Pelle, J.L. Dubois-Rande, and S. Adnot Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin J. Am. Coll. Cardiol. 41 2003 1198 1204
13. S. Rolin, J. Hanson, C. Vastersaegher, C. Cherdon, D. Pratico, B. Masereel, and J.M. Dogne BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2 alpha in vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents Prostaglandins Other Lipid Mediat. 84 2007 14 23
14. X. Norel Prostanoid receptors in the human vascular wall The Scientific World Journal 7 2007 1359 1374
15. S.E. Akopov, A.N. Orekhov, V.V. Tertov, K.A. Khashimov, E.S. Gabrielyan, and V.N. Smirnov Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. The effect of calcium antagonists Atherosclerosis 72 1988 245 248
16. T. Ishimitsu, Y. Uehara, M. Ishii, T. Ikeda, H. Matsuoka, and T. Sugimoto Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats Hypertension 12 1988 46 51
17. Y. Uehara, T. Ishimitsu, K. Kimura, M. Ishii, T. Ikeda, and T. Sugimoto Regulatory effects of eicosanoids on thymidine uptake by vascular smooth muscle cells of rats Prostaglandins 36 1988 847 857
18. T. Nagata, Y. Uehara, A. Numabe, T. Ishimitsu, N. Hirawa, T. Ikeda, H. Matsuoka, and T. Sugimoto Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats Am. J. Physiol. 263 1992 H1331 H1338
19. A. Sachinidis, M. Flesch, Y. Ko, K. Schror, M. Bohm, R. Dusing, and H. Vetter Thromboxane A2 and vascular smooth muscle cell proliferation Hypertension 26 1995 771 780
20. S. Ali, M.G. Davis, M.W. Becker, and G.W. Dorn 2nd Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor J. Biol. Chem. 268 1993 17397 17403
21. D.A. Jones, C.W. Benjamin, and D.A. Linseman Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades Mol. Pharmacol. 48 1995 890 896
22. R. Pakala, J.T. Willerson, and C.R. Benedict Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation Circulation 96 1997 2280 2286
23. K.S. Sakariassen, E.A. Femia, F.M. Daray, G.M. Podda, C. Razzari, M. Pugliano, A.E. Errasti, A.R. Armesto, W. Nowak, P. Alberts, J.P. Meyer, A.S. Sorensen, M. Cattaneo, and R.P. Rothlin EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin Thromb. Res. 130 2012 746 752
24. A. Tello-Montoliu, F. Rollini, B. Desai, G. Pasqualino, R. Patel, A.S. Sorensen, K.S. Sakariassen, and D.J. Angiolillo Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers J. Thromb. Thrombolysis 34 2012 297 299
25. P. Fontana, P. Alberts, K.S. Sakariassen, H. Bounameaux, J.P. Meyer, and A. Santana Sorensen The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin J. Throm. Haemost. 9 2011 2109 2111
26. A. Richardson, K.S. Sakariassen, J.P. Meyer, P. Alberts, and A.S. Sorensen Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation Eur. J. Clin. Pharmacol. 69 2013 459 465
27. M. Bäck, D.X. Bu, R. Branstrom, Y. Sheikine, Z.Q. Yan, and G.K. Hansson Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia Proc. Natl. Acad. Sci. U.S.A. 102 2005 17501 17506
28. C. Weber, W. Erl, A. Pietsch, and P.C. Weber Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells Circulation 91 1995 1914 1917
29. T. Ishizuka, S. Sawada, K. Sugama, and A. Kurita Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein-1 (MCP-1) expression by stimulated vascular endothelial cells Clin. Exp. Immunol. 120 2000 71 78
30. N. Leitinger, J. Huber, C. Rizza, D. Mechtcheriakova, V. Bochkov, Y. Koshelnick, J.A. Berliner, and B.R. Binder The isoprostane 8-iso-PGF(2alpha) stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation FASEB J. 15 2001 1254 1256
31. Y. Cheng, S.C. Austin, B. Rocca, B.H. Koller, T.M. Coffman, T. Grosser, J.A. Lawson, and G.A. FitzGerald Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 2002 539 541
32. T. Grosser, S. Fries, and G.A. FitzGerald Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 116 2006 4 15
33. M.G. Bousser, P. Amarenco, A. Chamorro, M. Fisher, I. Ford, K.M. Fox, M.G. Hennerici, H.P. Mattle, P.M. Rothwell, A. de Cordoue, and M.D. Fratacci Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial Lancet 377 2011 2013 2022
34. K. Hanasaki, T. Nakano, and H. Arita Receptor-mediated mitogenic effect of thromboxane A2 in vascular smooth muscle cells Biochem. Pharmacol. 40 1990 2535 2542
35. S. Ratti, P. Quarato, C. Casagrande, R. Fumagalli, and A. Corsini Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes Eur. J. Pharmacol. 355 1998 77 83
36. T. Grosser, T.P. Zucker, A.A. Weber, K. Schulte, A. Sachinidis, H. Vetter, and K. Schror Thromboxane A2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen Eur. J. Pharmacol. 319 1997 327 332
37. T.P. Zucker, D. Bonisch, S. Muck, A.A. Weber, E. Bretschneider, E. Glusa, and K. Schror Thrombin-induced mitogenesis in coronary artery smooth muscle cells is potentiated by thromboxane A2 and involves upregulation of thromboxane receptor mRNA Circulation 97 1998 589 595
38. S. Koba, R. Pakala, T. Watanabe, T. Katagiri, and C.R. Benedict Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation Prostaglandins Leukot. Essent. Fatty Acids 63 2000 329 335
39. S.T. Crowley, E.C. Dempsey, K.B. Horwitz, and L.D. Horwitz Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate Circulation 90 1994 1908 1918
40. P. Gelosa, G. Sevin, A. Pignieri, S. Budelli, L. Castiglioni, V. Blanc-Guillemaud, L. Lerond, E. Tremoli, and L. Sironi Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis Am. J. Physiol. Heart Circ. Physiol. 300 2011 H762 H768
41. E. Gautier, C. Arnaud, M. Bäck, J.L. Pepin, M.H. Petri, J.P. Baguet, R. Tamisier, P. Levy, and F. Stanke-Labesque Intermittent hypoxia activated cyclooxygenase pathway: role in atherosclerosis Eur. Respir. J. 2013 404 413
42. M. Bäck, L. Yin, and E. Ingelsson Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib Eur. Heart J. 33 2012 1928 1933